Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease

Identifieur interne : 000004 ( Pmc/Checkpoint ); précédent : 000003; suivant : 000005

Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease

Auteurs : Daniela Berg [Allemagne] ; Ronald B. Postuma [Canada] ; Bastiaan Bloem [Pays-Bas] ; Piu Chan [République populaire de Chine] ; Bruno Dubois [France] ; Thomas Gasser [Allemagne] ; Christopher G. Goetz [États-Unis] ; Glenda M. Halliday [Australie] ; John Hardy [Royaume-Uni] ; Anthony E. Lang [Canada] ; Irene Litvan [États-Unis] ; Kenneth Marek [États-Unis] ; José Obeso [Espagne] ; Wolfgang Oertel [Allemagne] ; C Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Matthew Stern [États-Unis] ; Günther Deuschl [Allemagne]

Source :

RBID : PMC:4204150

Abstract

With advances in knowledge disease, boundaries may change. Occasionally, these changes are of such a magnitude that they require redefinition of the disease. In recognition of the profound changes in our understanding of Parkinson's disease (PD), the International Parkinson and Movement Disorders Society (MDS) commissioned a task force to consider a redefinition of PD. This review is a discussion article, intended as the introductory statement of the task force. Several critical issues were identified that challenge current PD definitions. First, new findings challenge the central role of the classical pathologic criteria as the arbiter of diagnosis, notably genetic cases without synuclein deposition, the high prevalence of incidental Lewy body (LB) deposition, and the nonmotor prodrome of PD. It remains unclear, however, whether these challenges merit a change in the pathologic gold standard, especially considering the limitations of alternate gold standards. Second, the increasing recognition of dementia in PD challenges the distinction between diffuse LB disease and PD. Consideration might be given to removing dementia as an exclusion criterion for PD diagnosis. Third, there is increasing recognition of disease heterogeneity, suggesting that PD subtypes should be formally identified; however, current subtype classifications may not be sufficiently robust to warrant formal delineation. Fourth, the recognition of a nonmotor prodrome of PD requires that new diagnostic criteria for early-stage and prodromal PD should be created; here, essential features of these criteria are proposed. Finally, there is a need to create new MDS diagnostic criteria that take these changes in disease definition into consideration. © 2014 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.


Url:
DOI: 10.1002/mds.25844
PubMed: 24619848
PubMed Central: 4204150


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:4204150

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease</title>
<author>
<name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases</institution>
<addr-line>Tuebingen, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Tuebingen</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Neurology, Montreal General Hospital</institution>
<addr-line>Montreal, Quebec, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Montreal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bloem, Bastiaan" sort="Bloem, Bastiaan" uniqKey="Bloem B" first="Bastiaan" last="Bloem">Bastiaan Bloem</name>
<affiliation wicri:level="1">
<nlm:aff id="au3">
<institution>Department of Neurology, Radboud University Nijmegen Medical Center</institution>
<addr-line>Nijmegen, the Netherlands</addr-line>
</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Nijmegen</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Chan, Piu" sort="Chan, Piu" uniqKey="Chan P" first="Piu" last="Chan">Piu Chan</name>
<affiliation wicri:level="1">
<nlm:aff id="au4">
<institution>Xuanwu Hospital of Capital Medical University</institution>
<addr-line>Beijing, People's Republic of China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1">
<nlm:aff id="au5">
<institution>Department of neurology, Salpêtrière Hospital, APHP, University Paris 6</institution>
<addr-line>UPMC, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>UPMC, Paris</wicri:regionArea>
<placeName>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases</institution>
<addr-line>Tuebingen, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Tuebingen</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2">
<nlm:aff id="au6">
<institution>Rush University Medical Center</institution>
<addr-line>Chicago, Illinois, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M" last="Halliday">Glenda M. Halliday</name>
<affiliation wicri:level="1">
<nlm:aff id="au7">
<institution>Neuroscience Research, Randwick, Australia and the University of New South Wales</institution>
<addr-line>Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Sydney</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Hardy, John" sort="Hardy, John" uniqKey="Hardy J" first="John" last="Hardy">John Hardy</name>
<affiliation wicri:level="1">
<nlm:aff id="au8">
<institution>Department of Molecular Neuroscience, UCL Institute of Neurology</institution>
<addr-line>London, UK</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1">
<nlm:aff id="au9">
<institution>Edmond J Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital and the University of Toronto</institution>
<addr-line>Toronto, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name>
<affiliation wicri:level="2">
<nlm:aff id="au10">
<institution>Department of Neurosciences, University of California San Diego</institution>
<addr-line>La Jolla, California, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>La Jolla, California</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation wicri:level="2">
<nlm:aff id="au11">
<institution>Institute for Neurodegenerative Disorders</institution>
<addr-line>New Haven, Connecticut, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New Haven, Connecticut</wicri:regionArea>
<placeName>
<region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Obeso, Jose" sort="Obeso, Jose" uniqKey="Obeso J" first="José" last="Obeso">José Obeso</name>
<affiliation wicri:level="1">
<nlm:aff id="au12">
<institution>University of Navarra-FIMA</institution>
<addr-line>Pamplona, Spain</addr-line>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Pamplona</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>
<affiliation wicri:level="1">
<nlm:aff id="au13">
<institution>Department of Neurology, Philipps University of Marburg</institution>
<addr-line>Marburg, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Marburg</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
<affiliation wicri:level="2">
<nlm:aff id="au14">
<institution>Department of Neurology, The Mount Sinai Hospital</institution>
<addr-line>New York, New York, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<nlm:aff id="au15">
<institution>Department of Neurology, Innsbruck Medical University</institution>
<addr-line>Innsbruck, Austria</addr-line>
</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Innsbruck</wicri:regionArea>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
<affiliation wicri:level="2">
<nlm:aff id="au16">
<institution>Penn Neurological Institute</institution>
<addr-line>Philadelphia, Pennsylvania, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Philadelphia, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
<affiliation wicri:level="1">
<nlm:aff id="au17">
<institution>Department of Neurology, Christian-Albrechts University</institution>
<addr-line>Kiel, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Kiel</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">24619848</idno>
<idno type="pmc">4204150</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204150</idno>
<idno type="RBID">PMC:4204150</idno>
<idno type="doi">10.1002/mds.25844</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000439</idno>
<idno type="wicri:Area/Pmc/Curation">000439</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000004</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease</title>
<author>
<name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases</institution>
<addr-line>Tuebingen, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Tuebingen</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Neurology, Montreal General Hospital</institution>
<addr-line>Montreal, Quebec, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Montreal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bloem, Bastiaan" sort="Bloem, Bastiaan" uniqKey="Bloem B" first="Bastiaan" last="Bloem">Bastiaan Bloem</name>
<affiliation wicri:level="1">
<nlm:aff id="au3">
<institution>Department of Neurology, Radboud University Nijmegen Medical Center</institution>
<addr-line>Nijmegen, the Netherlands</addr-line>
</nlm:aff>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Nijmegen</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Chan, Piu" sort="Chan, Piu" uniqKey="Chan P" first="Piu" last="Chan">Piu Chan</name>
<affiliation wicri:level="1">
<nlm:aff id="au4">
<institution>Xuanwu Hospital of Capital Medical University</institution>
<addr-line>Beijing, People's Republic of China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1">
<nlm:aff id="au5">
<institution>Department of neurology, Salpêtrière Hospital, APHP, University Paris 6</institution>
<addr-line>UPMC, Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>UPMC, Paris</wicri:regionArea>
<placeName>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases</institution>
<addr-line>Tuebingen, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Tuebingen</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2">
<nlm:aff id="au6">
<institution>Rush University Medical Center</institution>
<addr-line>Chicago, Illinois, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Chicago, Illinois</wicri:regionArea>
<placeName>
<region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M" last="Halliday">Glenda M. Halliday</name>
<affiliation wicri:level="1">
<nlm:aff id="au7">
<institution>Neuroscience Research, Randwick, Australia and the University of New South Wales</institution>
<addr-line>Sydney, Australia</addr-line>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Sydney</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Hardy, John" sort="Hardy, John" uniqKey="Hardy J" first="John" last="Hardy">John Hardy</name>
<affiliation wicri:level="1">
<nlm:aff id="au8">
<institution>Department of Molecular Neuroscience, UCL Institute of Neurology</institution>
<addr-line>London, UK</addr-line>
</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1">
<nlm:aff id="au9">
<institution>Edmond J Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital and the University of Toronto</institution>
<addr-line>Toronto, Canada</addr-line>
</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name>
<affiliation wicri:level="2">
<nlm:aff id="au10">
<institution>Department of Neurosciences, University of California San Diego</institution>
<addr-line>La Jolla, California, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>La Jolla, California</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation wicri:level="2">
<nlm:aff id="au11">
<institution>Institute for Neurodegenerative Disorders</institution>
<addr-line>New Haven, Connecticut, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New Haven, Connecticut</wicri:regionArea>
<placeName>
<region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Obeso, Jose" sort="Obeso, Jose" uniqKey="Obeso J" first="José" last="Obeso">José Obeso</name>
<affiliation wicri:level="1">
<nlm:aff id="au12">
<institution>University of Navarra-FIMA</institution>
<addr-line>Pamplona, Spain</addr-line>
</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Pamplona</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>
<affiliation wicri:level="1">
<nlm:aff id="au13">
<institution>Department of Neurology, Philipps University of Marburg</institution>
<addr-line>Marburg, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Marburg</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
<affiliation wicri:level="2">
<nlm:aff id="au14">
<institution>Department of Neurology, The Mount Sinai Hospital</institution>
<addr-line>New York, New York, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<nlm:aff id="au15">
<institution>Department of Neurology, Innsbruck Medical University</institution>
<addr-line>Innsbruck, Austria</addr-line>
</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Innsbruck</wicri:regionArea>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
<affiliation wicri:level="2">
<nlm:aff id="au16">
<institution>Penn Neurological Institute</institution>
<addr-line>Philadelphia, Pennsylvania, USA</addr-line>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Philadelphia, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
<affiliation wicri:level="1">
<nlm:aff id="au17">
<institution>Department of Neurology, Christian-Albrechts University</institution>
<addr-line>Kiel, Germany</addr-line>
</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Kiel</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Movement Disorders</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>With advances in knowledge disease, boundaries may change. Occasionally, these changes are of such a magnitude that they require redefinition of the disease. In recognition of the profound changes in our understanding of Parkinson's disease (PD), the International Parkinson and Movement Disorders Society (MDS) commissioned a task force to consider a redefinition of PD. This review is a discussion article, intended as the introductory statement of the task force. Several critical issues were identified that challenge current PD definitions. First, new findings challenge the central role of the classical pathologic criteria as the arbiter of diagnosis, notably genetic cases without synuclein deposition, the high prevalence of incidental Lewy body (LB) deposition, and the nonmotor prodrome of PD. It remains unclear, however, whether these challenges merit a change in the pathologic gold standard, especially considering the limitations of alternate gold standards. Second, the increasing recognition of dementia in PD challenges the distinction between diffuse LB disease and PD. Consideration might be given to removing dementia as an exclusion criterion for PD diagnosis. Third, there is increasing recognition of disease heterogeneity, suggesting that PD subtypes should be formally identified; however, current subtype classifications may not be sufficiently robust to warrant formal delineation. Fourth, the recognition of a nonmotor prodrome of PD requires that new diagnostic criteria for early-stage and prodromal PD should be created; here, essential features of these criteria are proposed. Finally, there is a need to create new MDS diagnostic criteria that take these changes in disease definition into consideration. © 2014 The Authors.
<italic>Movement</italic>
Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</p>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Wider, C" uniqKey="Wider C">C Wider</name>
</author>
<author>
<name sortKey="Dickson, Dw" uniqKey="Dickson D">DW Dickson</name>
</author>
<author>
<name sortKey="Wszolek, Zk" uniqKey="Wszolek Z">ZK Wszolek</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Poulopoulos, M" uniqKey="Poulopoulos M">M Poulopoulos</name>
</author>
<author>
<name sortKey="Levy, Oa" uniqKey="Levy O">OA Levy</name>
</author>
<author>
<name sortKey="Alcalay, Rn" uniqKey="Alcalay R">RN Alcalay</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Beach, Tg" uniqKey="Beach T">TG Beach</name>
</author>
<author>
<name sortKey="Adler, Ch" uniqKey="Adler C">CH Adler</name>
</author>
<author>
<name sortKey="Sue, Li" uniqKey="Sue L">LI Sue</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Parkkinen, L" uniqKey="Parkkinen L">L Parkkinen</name>
</author>
<author>
<name sortKey="Pirttila, T" uniqKey="Pirttila T">T Pirttila</name>
</author>
<author>
<name sortKey="Alafuzoff, I" uniqKey="Alafuzoff I">I Alafuzoff</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dickson, Dw" uniqKey="Dickson D">DW Dickson</name>
</author>
<author>
<name sortKey="Fujishiro, H" uniqKey="Fujishiro H">H Fujishiro</name>
</author>
<author>
<name sortKey="Delledonne, A" uniqKey="Delledonne A">A Delledonne</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Braak, H" uniqKey="Braak H">H Braak</name>
</author>
<author>
<name sortKey="Del Tredici, K" uniqKey="Del Tredici K">K Del Tredici</name>
</author>
<author>
<name sortKey="Rub, U" uniqKey="Rub U">U Rub</name>
</author>
<author>
<name sortKey="De Vos, Ra" uniqKey="De Vos R">RA de Vos</name>
</author>
<author>
<name sortKey="Jansen Steur, En" uniqKey="Jansen Steur E">EN Jansen Steur</name>
</author>
<author>
<name sortKey="Braak, E" uniqKey="Braak E">E Braak</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Orimo, S" uniqKey="Orimo S">S Orimo</name>
</author>
<author>
<name sortKey="Takahashi, A" uniqKey="Takahashi A">A Takahashi</name>
</author>
<author>
<name sortKey="Uchihara, T" uniqKey="Uchihara T">T Uchihara</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Milber, Jm" uniqKey="Milber J">JM Milber</name>
</author>
<author>
<name sortKey="Noorigian, Jv" uniqKey="Noorigian J">JV Noorigian</name>
</author>
<author>
<name sortKey="Morley, Jf" uniqKey="Morley J">JF Morley</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cheng, Hc" uniqKey="Cheng H">HC Cheng</name>
</author>
<author>
<name sortKey="Ulane, Cm" uniqKey="Ulane C">CM Ulane</name>
</author>
<author>
<name sortKey="Burke, Re" uniqKey="Burke R">RE Burke</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wirdefeldt, K" uniqKey="Wirdefeldt K">K Wirdefeldt</name>
</author>
<author>
<name sortKey="Gatz, M" uniqKey="Gatz M">M Gatz</name>
</author>
<author>
<name sortKey="Schalling, M" uniqKey="Schalling M">M Schalling</name>
</author>
<author>
<name sortKey="Pedersen, Nl" uniqKey="Pedersen N">NL Pedersen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Tanner, Cm" uniqKey="Tanner C">CM Tanner</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zimprich, A" uniqKey="Zimprich A">A Zimprich</name>
</author>
<author>
<name sortKey="Biskup, S" uniqKey="Biskup S">S Biskup</name>
</author>
<author>
<name sortKey="Leitner, P" uniqKey="Leitner P">P Leitner</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Marras, C" uniqKey="Marras C">C Marras</name>
</author>
<author>
<name sortKey="Lohmann, K" uniqKey="Lohmann K">K Lohmann</name>
</author>
<author>
<name sortKey="Lang, A" uniqKey="Lang A">A Lang</name>
</author>
<author>
<name sortKey="Klein, C" uniqKey="Klein C">C Klein</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mckeith, I" uniqKey="Mckeith I">I McKeith</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dubois, B" uniqKey="Dubois B">B Dubois</name>
</author>
<author>
<name sortKey="Burn, D" uniqKey="Burn D">D Burn</name>
</author>
<author>
<name sortKey="Goetz, C" uniqKey="Goetz C">C Goetz</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lippa, Cf" uniqKey="Lippa C">CF Lippa</name>
</author>
<author>
<name sortKey="Duda, Je" uniqKey="Duda J">JE Duda</name>
</author>
<author>
<name sortKey="Grossman, M" uniqKey="Grossman M">M Grossman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dugger, Bn" uniqKey="Dugger B">BN Dugger</name>
</author>
<author>
<name sortKey="Boeve, Bf" uniqKey="Boeve B">BF Boeve</name>
</author>
<author>
<name sortKey="Murray, Me" uniqKey="Murray M">ME Murray</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Klein, Jc" uniqKey="Klein J">JC Klein</name>
</author>
<author>
<name sortKey="Eggers, C" uniqKey="Eggers C">C Eggers</name>
</author>
<author>
<name sortKey="Kalbe, E" uniqKey="Kalbe E">E Kalbe</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Watson, R" uniqKey="Watson R">R Watson</name>
</author>
<author>
<name sortKey="Blamire, Am" uniqKey="Blamire A">AM Blamire</name>
</author>
<author>
<name sortKey="Colloby, Sj" uniqKey="Colloby S">SJ Colloby</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Postuma, Rb" uniqKey="Postuma R">RB Postuma</name>
</author>
<author>
<name sortKey="Gagnon, Jf" uniqKey="Gagnon J">JF Gagnon</name>
</author>
<author>
<name sortKey="Vendette, M" uniqKey="Vendette M">M Vendette</name>
</author>
<author>
<name sortKey="Montplaisir, Jy" uniqKey="Montplaisir J">JY Montplaisir</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Johansen, Kk" uniqKey="Johansen K">KK Johansen</name>
</author>
<author>
<name sortKey="White, Lr" uniqKey="White L">LR White</name>
</author>
<author>
<name sortKey="Sando, Sb" uniqKey="Sando S">SB Sando</name>
</author>
<author>
<name sortKey="Aasly, Jo" uniqKey="Aasly J">JO Aasly</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Goldman, Jg" uniqKey="Goldman J">JG Goldman</name>
</author>
<author>
<name sortKey="Goetz, Cg" uniqKey="Goetz C">CG Goetz</name>
</author>
<author>
<name sortKey="Brandabur, M" uniqKey="Brandabur M">M Brandabur</name>
</author>
<author>
<name sortKey="Sanfilippo, M" uniqKey="Sanfilippo M">M Sanfilippo</name>
</author>
<author>
<name sortKey="Stebbins, Gt" uniqKey="Stebbins G">GT Stebbins</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mckeith, Ig" uniqKey="Mckeith I">IG McKeith</name>
</author>
<author>
<name sortKey="Dickson, Dw" uniqKey="Dickson D">DW Dickson</name>
</author>
<author>
<name sortKey="Lowe, J" uniqKey="Lowe J">J Lowe</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Marras, C" uniqKey="Marras C">C Marras</name>
</author>
<author>
<name sortKey="Lang, A" uniqKey="Lang A">A Lang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Van Rooden, Sm" uniqKey="Van Rooden S">SM van Rooden</name>
</author>
<author>
<name sortKey="Colas, F" uniqKey="Colas F">F Colas</name>
</author>
<author>
<name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Van Rooden, Sm" uniqKey="Van Rooden S">SM van Rooden</name>
</author>
<author>
<name sortKey="Heiser, Wj" uniqKey="Heiser W">WJ Heiser</name>
</author>
<author>
<name sortKey="Kok, Jn" uniqKey="Kok J">JN Kok</name>
</author>
<author>
<name sortKey="Verbaan, D" uniqKey="Verbaan D">D Verbaan</name>
</author>
<author>
<name sortKey="Van Hilten, Jj" uniqKey="Van Hilten J">JJ van Hilten</name>
</author>
<author>
<name sortKey="Marinus, J" uniqKey="Marinus J">J Marinus</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Reijnders, Js" uniqKey="Reijnders J">JS Reijnders</name>
</author>
<author>
<name sortKey="Ehrt, U" uniqKey="Ehrt U">U Ehrt</name>
</author>
<author>
<name sortKey="Lousberg, R" uniqKey="Lousberg R">R Lousberg</name>
</author>
<author>
<name sortKey="Aarsland, D" uniqKey="Aarsland D">D Aarsland</name>
</author>
<author>
<name sortKey="Leentjens, Af" uniqKey="Leentjens A">AF Leentjens</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Post, B" uniqKey="Post B">B Post</name>
</author>
<author>
<name sortKey="Speelman, Jd" uniqKey="Speelman J">JD Speelman</name>
</author>
<author>
<name sortKey="De Haan, Rj" uniqKey="De Haan R">RJ de Haan</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lewis, Sj" uniqKey="Lewis S">SJ Lewis</name>
</author>
<author>
<name sortKey="Foltynie, T" uniqKey="Foltynie T">T Foltynie</name>
</author>
<author>
<name sortKey="Blackwell, Ad" uniqKey="Blackwell A">AD Blackwell</name>
</author>
<author>
<name sortKey="Robbins, Tw" uniqKey="Robbins T">TW Robbins</name>
</author>
<author>
<name sortKey="Owen, Am" uniqKey="Owen A">AM Owen</name>
</author>
<author>
<name sortKey="Barker, Ra" uniqKey="Barker R">RA Barker</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Graham, Jm" uniqKey="Graham J">JM Graham</name>
</author>
<author>
<name sortKey="Sagar, Hj" uniqKey="Sagar H">HJ Sagar</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Schrag, A" uniqKey="Schrag A">A Schrag</name>
</author>
<author>
<name sortKey="Quinn, Np" uniqKey="Quinn N">NP Quinn</name>
</author>
<author>
<name sortKey="Ben Shlomo, Y" uniqKey="Ben Shlomo Y">Y Ben-Shlomo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Selikhova, M" uniqKey="Selikhova M">M Selikhova</name>
</author>
<author>
<name sortKey="Williams, Dr" uniqKey="Williams D">DR Williams</name>
</author>
<author>
<name sortKey="Kempster, Pa" uniqKey="Kempster P">PA Kempster</name>
</author>
<author>
<name sortKey="Holton, Jl" uniqKey="Holton J">JL Holton</name>
</author>
<author>
<name sortKey="Revesz, T" uniqKey="Revesz T">T Revesz</name>
</author>
<author>
<name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Suchowersky, O" uniqKey="Suchowersky O">O Suchowersky</name>
</author>
<author>
<name sortKey="Reich, S" uniqKey="Reich S">S Reich</name>
</author>
<author>
<name sortKey="Perlmutter, J" uniqKey="Perlmutter J">J Perlmutter</name>
</author>
<author>
<name sortKey="Zesiewicz, T" uniqKey="Zesiewicz T">T Zesiewicz</name>
</author>
<author>
<name sortKey="Gronseth, G" uniqKey="Gronseth G">G Gronseth</name>
</author>
<author>
<name sortKey="Weiner, Wj" uniqKey="Weiner W">WJ Weiner</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Marras, C" uniqKey="Marras C">C Marras</name>
</author>
<author>
<name sortKey="Rochon, P" uniqKey="Rochon P">P Rochon</name>
</author>
<author>
<name sortKey="Lang, Ae" uniqKey="Lang A">AE Lang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Post, B" uniqKey="Post B">B Post</name>
</author>
<author>
<name sortKey="Merkus, Mp" uniqKey="Merkus M">MP Merkus</name>
</author>
<author>
<name sortKey="De Haan, Rj" uniqKey="De Haan R">RJ de Haan</name>
</author>
<author>
<name sortKey="Speelman, Jd" uniqKey="Speelman J">JD Speelman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bohnen, Ni" uniqKey="Bohnen N">NI Bohnen</name>
</author>
<author>
<name sortKey="Muller, Ml" uniqKey="Muller M">ML Muller</name>
</author>
<author>
<name sortKey="Kotagal, V" uniqKey="Kotagal V">V Kotagal</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Postuma, Rb" uniqKey="Postuma R">RB Postuma</name>
</author>
<author>
<name sortKey="Bertrand, Ja" uniqKey="Bertrand J">JA Bertrand</name>
</author>
<author>
<name sortKey="Montplaisir, J" uniqKey="Montplaisir J">J Montplaisir</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Romenets, Sr" uniqKey="Romenets S">SR Romenets</name>
</author>
<author>
<name sortKey="Gagnon, Jf" uniqKey="Gagnon J">JF Gagnon</name>
</author>
<author>
<name sortKey="Latreille, V" uniqKey="Latreille V">V Latreille</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wickremaratchi, Mm" uniqKey="Wickremaratchi M">MM Wickremaratchi</name>
</author>
<author>
<name sortKey="Perera, D" uniqKey="Perera D">D Perera</name>
</author>
<author>
<name sortKey="O Loghlen, C" uniqKey="O Loghlen C">C O'Loghlen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Van Den Eeden, Sk" uniqKey="Van Den Eeden S">SK Van Den Eeden</name>
</author>
<author>
<name sortKey="Tanner, Cm" uniqKey="Tanner C">CM Tanner</name>
</author>
<author>
<name sortKey="Bernstein, Al" uniqKey="Bernstein A">AL Bernstein</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Braak, H" uniqKey="Braak H">H Braak</name>
</author>
<author>
<name sortKey="Del, Tk" uniqKey="Del T">TK Del</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ross, Gw" uniqKey="Ross G">GW Ross</name>
</author>
<author>
<name sortKey="Petrovitch, H" uniqKey="Petrovitch H">H Petrovitch</name>
</author>
<author>
<name sortKey="Abbott, Rd" uniqKey="Abbott R">RD Abbott</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Abbott, Rd" uniqKey="Abbott R">RD Abbott</name>
</author>
<author>
<name sortKey="Ross, Gw" uniqKey="Ross G">GW Ross</name>
</author>
<author>
<name sortKey="Petrovitch, H" uniqKey="Petrovitch H">H Petrovitch</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Berg, D" uniqKey="Berg D">D Berg</name>
</author>
<author>
<name sortKey="Seppi, K" uniqKey="Seppi K">K Seppi</name>
</author>
<author>
<name sortKey="Behnke, S" uniqKey="Behnke S">S Behnke</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gibb, Wr" uniqKey="Gibb W">WR Gibb</name>
</author>
<author>
<name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gelb, Dj" uniqKey="Gelb D">DJ Gelb</name>
</author>
<author>
<name sortKey="Oliver, E" uniqKey="Oliver E">E Oliver</name>
</author>
<author>
<name sortKey="Gilman, S" uniqKey="Gilman S">S Gilman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Koller, Wc" uniqKey="Koller W">WC Koller</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calne, Db" uniqKey="Calne D">DB Calne</name>
</author>
<author>
<name sortKey="Snow, Bj" uniqKey="Snow B">BJ Snow</name>
</author>
<author>
<name sortKey="Lee, C" uniqKey="Lee C">C Lee</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ward, Cd" uniqKey="Ward C">CD Ward</name>
</author>
<author>
<name sortKey="Gibb, Wr" uniqKey="Gibb W">WR Gibb</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Rajput, Ah" uniqKey="Rajput A">AH Rajput</name>
</author>
<author>
<name sortKey="Rozdilsky, B" uniqKey="Rozdilsky B">B Rozdilsky</name>
</author>
<author>
<name sortKey="Rajput, A" uniqKey="Rajput A">A Rajput</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Larsen, Jp" uniqKey="Larsen J">JP Larsen</name>
</author>
<author>
<name sortKey="Dupont, E" uniqKey="Dupont E">E Dupont</name>
</author>
<author>
<name sortKey="Tandberg, E" uniqKey="Tandberg E">E Tandberg</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Aerts, Mb" uniqKey="Aerts M">MB Aerts</name>
</author>
<author>
<name sortKey="Esselink, Ra" uniqKey="Esselink R">RA Esselink</name>
</author>
<author>
<name sortKey="Post, B" uniqKey="Post B">B Post</name>
</author>
<author>
<name sortKey="Van De Warrenburg, Bp" uniqKey="Van De Warrenburg B">BP van de Warrenburg</name>
</author>
<author>
<name sortKey="Bloem, Br" uniqKey="Bloem B">BR Bloem</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Velseboer, Dc" uniqKey="Velseboer D">DC Velseboer</name>
</author>
<author>
<name sortKey="De Haan, Rj" uniqKey="De Haan R">RJ de Haan</name>
</author>
<author>
<name sortKey="Wieling, W" uniqKey="Wieling W">W Wieling</name>
</author>
<author>
<name sortKey="Goldstein, Ds" uniqKey="Goldstein D">DS Goldstein</name>
</author>
<author>
<name sortKey="De Bie, Rm" uniqKey="De Bie R">RM de Bie</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Martinez Martin, P" uniqKey="Martinez Martin P">P Martinez-Martin</name>
</author>
<author>
<name sortKey="Rodriguez Blazquez, C" uniqKey="Rodriguez Blazquez C">C Rodriguez-Blazquez</name>
</author>
<author>
<name sortKey="Kurtis, Mm" uniqKey="Kurtis M">MM Kurtis</name>
</author>
<author>
<name sortKey="Chaudhuri, Kr" uniqKey="Chaudhuri K">KR Chaudhuri</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hughes, Aj" uniqKey="Hughes A">AJ Hughes</name>
</author>
<author>
<name sortKey="Daniel, Se" uniqKey="Daniel S">SE Daniel</name>
</author>
<author>
<name sortKey="Kilford, L" uniqKey="Kilford L">L Kilford</name>
</author>
<author>
<name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Louis, Ed" uniqKey="Louis E">ED Louis</name>
</author>
<author>
<name sortKey="Bennett, Da" uniqKey="Bennett D">DA Bennett</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Buchman, As" uniqKey="Buchman A">AS Buchman</name>
</author>
<author>
<name sortKey="Shulman, Jm" uniqKey="Shulman J">JM Shulman</name>
</author>
<author>
<name sortKey="Nag, S" uniqKey="Nag S">S Nag</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Uemura, Y" uniqKey="Uemura Y">Y Uemura</name>
</author>
<author>
<name sortKey="Wada Isoe, K" uniqKey="Wada Isoe K">K Wada-Isoe</name>
</author>
<author>
<name sortKey="Nakashita, S" uniqKey="Nakashita S">S Nakashita</name>
</author>
<author>
<name sortKey="Nakashima, K" uniqKey="Nakashima K">K Nakashima</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lost, D" uniqKey="Lost D">D Lost</name>
</author>
<author>
<name sortKey="Tang, Mx" uniqKey="Tang M">MX Tang</name>
</author>
<author>
<name sortKey="Schupf, N" uniqKey="Schupf N">N Schupf</name>
</author>
<author>
<name sortKey="Mayeux, R" uniqKey="Mayeux R">R Mayeux</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Buchman, As" uniqKey="Buchman A">AS Buchman</name>
</author>
<author>
<name sortKey="Nag, S" uniqKey="Nag S">S Nag</name>
</author>
<author>
<name sortKey="Shulman, Jm" uniqKey="Shulman J">JM Shulman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hughes, Aj" uniqKey="Hughes A">AJ Hughes</name>
</author>
<author>
<name sortKey="Daniel, Se" uniqKey="Daniel S">SE Daniel</name>
</author>
<author>
<name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Tolosa, E" uniqKey="Tolosa E">E Tolosa</name>
</author>
<author>
<name sortKey="Wenning, G" uniqKey="Wenning G">G Wenning</name>
</author>
<author>
<name sortKey="Poewe, W" uniqKey="Poewe W">W Poewe</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hughes, Aj" uniqKey="Hughes A">AJ Hughes</name>
</author>
<author>
<name sortKey="Daniel, Se" uniqKey="Daniel S">SE Daniel</name>
</author>
<author>
<name sortKey="Ben Shlomo, Y" uniqKey="Ben Shlomo Y">Y Ben-Shlomo</name>
</author>
<author>
<name sortKey="Lees, Aj" uniqKey="Lees A">AJ Lees</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mov Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Mov. Disord</journal-id>
<journal-id journal-id-type="publisher-id">mds</journal-id>
<journal-title-group>
<journal-title>Movement Disorders</journal-title>
</journal-title-group>
<issn pub-type="ppub">0885-3185</issn>
<issn pub-type="epub">1531-8257</issn>
<publisher>
<publisher-name>BlackWell Publishing Ltd</publisher-name>
<publisher-loc>Oxford, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">24619848</article-id>
<article-id pub-id-type="pmc">4204150</article-id>
<article-id pub-id-type="doi">10.1002/mds.25844</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Featured Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Berg</surname>
<given-names>Daniela</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
<xref ref-type="author-notes" rid="fn1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Postuma</surname>
<given-names>Ronald B</given-names>
</name>
<degrees>MD, MSc</degrees>
<xref ref-type="aff" rid="au2">2</xref>
<xref ref-type="author-notes" rid="fn1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bloem</surname>
<given-names>Bastiaan</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="au3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chan</surname>
<given-names>Piu</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="au4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dubois</surname>
<given-names>Bruno</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="au5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gasser</surname>
<given-names>Thomas</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goetz</surname>
<given-names>Christopher G</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Halliday</surname>
<given-names>Glenda M</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="au7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hardy</surname>
<given-names>John</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="au8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lang</surname>
<given-names>Anthony E</given-names>
</name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="au9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Litvan</surname>
<given-names>Irene</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marek</surname>
<given-names>Kenneth</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Obeso</surname>
<given-names>José</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="au12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oertel</surname>
<given-names>Wolfgang</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olanow</surname>
<given-names>C Warren</given-names>
</name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="au14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Poewe</surname>
<given-names>Werner</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au15">15</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stern</surname>
<given-names>Matthew</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deuschl</surname>
<given-names>Günther</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="au17">17</xref>
</contrib>
<aff id="au1">
<label>1</label>
<institution>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Center of Neurodegenerative Diseases</institution>
<addr-line>Tuebingen, Germany</addr-line>
</aff>
<aff id="au2">
<label>2</label>
<institution>Department of Neurology, Montreal General Hospital</institution>
<addr-line>Montreal, Quebec, Canada</addr-line>
</aff>
<aff id="au3">
<label>3</label>
<institution>Department of Neurology, Radboud University Nijmegen Medical Center</institution>
<addr-line>Nijmegen, the Netherlands</addr-line>
</aff>
<aff id="au4">
<label>4</label>
<institution>Xuanwu Hospital of Capital Medical University</institution>
<addr-line>Beijing, People's Republic of China</addr-line>
</aff>
<aff id="au5">
<label>5</label>
<institution>Department of neurology, Salpêtrière Hospital, APHP, University Paris 6</institution>
<addr-line>UPMC, Paris, France</addr-line>
</aff>
<aff id="au6">
<label>6</label>
<institution>Rush University Medical Center</institution>
<addr-line>Chicago, Illinois, USA</addr-line>
</aff>
<aff id="au7">
<label>7</label>
<institution>Neuroscience Research, Randwick, Australia and the University of New South Wales</institution>
<addr-line>Sydney, Australia</addr-line>
</aff>
<aff id="au8">
<label>8</label>
<institution>Department of Molecular Neuroscience, UCL Institute of Neurology</institution>
<addr-line>London, UK</addr-line>
</aff>
<aff id="au9">
<label>9</label>
<institution>Edmond J Safra Program in Parkinson's Disease, Division of Neurology, Toronto Western Hospital and the University of Toronto</institution>
<addr-line>Toronto, Canada</addr-line>
</aff>
<aff id="au10">
<label>10</label>
<institution>Department of Neurosciences, University of California San Diego</institution>
<addr-line>La Jolla, California, USA</addr-line>
</aff>
<aff id="au11">
<label>11</label>
<institution>Institute for Neurodegenerative Disorders</institution>
<addr-line>New Haven, Connecticut, USA</addr-line>
</aff>
<aff id="au12">
<label>12</label>
<institution>University of Navarra-FIMA</institution>
<addr-line>Pamplona, Spain</addr-line>
</aff>
<aff id="au13">
<label>13</label>
<institution>Department of Neurology, Philipps University of Marburg</institution>
<addr-line>Marburg, Germany</addr-line>
</aff>
<aff id="au14">
<label>14</label>
<institution>Department of Neurology, The Mount Sinai Hospital</institution>
<addr-line>New York, New York, USA</addr-line>
</aff>
<aff id="au15">
<label>15</label>
<institution>Department of Neurology, Innsbruck Medical University</institution>
<addr-line>Innsbruck, Austria</addr-line>
</aff>
<aff id="au16">
<label>16</label>
<institution>Penn Neurological Institute</institution>
<addr-line>Philadelphia, Pennsylvania, USA</addr-line>
</aff>
<aff id="au17">
<label>17</label>
<institution>Department of Neurology, Christian-Albrechts University</institution>
<addr-line>Kiel, Germany</addr-line>
</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">*
<bold>Correspondence to:</bold>
Dr. Daniela Berg, Hertie Institute of Clinical Brain Research, HoppeSeyler-Straße 3, 72076 Tubingen, Germany;
<email>Daniela.berg@uni-tuebingen.de</email>
</corresp>
<fn>
<p>
<bold>Relevant conflicts of interest/financial disclosures</bold>
: Nothing to report.</p>
</fn>
<fn>
<p>Full financial disclosures and author roles may be found in the online version of this article.</p>
</fn>
<fn id="fn1">
<label></label>
<p>Drs. Berg and Postuma contributed equally.</p>
</fn>
<fn>
<p>The copyright line for this article was changed on October 21, 2014 after original online publication.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>4</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>3</month>
<year>2014</year>
</pub-date>
<volume>29</volume>
<issue>4</issue>
<fpage>454</fpage>
<lpage>462</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>4</month>
<year>2013</year>
</date>
<date date-type="rev-recd">
<day>27</day>
<month>11</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>12</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>© 2014 The Authors.
<italic>Movement</italic>
Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
<license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>With advances in knowledge disease, boundaries may change. Occasionally, these changes are of such a magnitude that they require redefinition of the disease. In recognition of the profound changes in our understanding of Parkinson's disease (PD), the International Parkinson and Movement Disorders Society (MDS) commissioned a task force to consider a redefinition of PD. This review is a discussion article, intended as the introductory statement of the task force. Several critical issues were identified that challenge current PD definitions. First, new findings challenge the central role of the classical pathologic criteria as the arbiter of diagnosis, notably genetic cases without synuclein deposition, the high prevalence of incidental Lewy body (LB) deposition, and the nonmotor prodrome of PD. It remains unclear, however, whether these challenges merit a change in the pathologic gold standard, especially considering the limitations of alternate gold standards. Second, the increasing recognition of dementia in PD challenges the distinction between diffuse LB disease and PD. Consideration might be given to removing dementia as an exclusion criterion for PD diagnosis. Third, there is increasing recognition of disease heterogeneity, suggesting that PD subtypes should be formally identified; however, current subtype classifications may not be sufficiently robust to warrant formal delineation. Fourth, the recognition of a nonmotor prodrome of PD requires that new diagnostic criteria for early-stage and prodromal PD should be created; here, essential features of these criteria are proposed. Finally, there is a need to create new MDS diagnostic criteria that take these changes in disease definition into consideration. © 2014 The Authors.
<italic>Movement</italic>
Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</p>
</abstract>
<kwd-group>
<kwd>redefinition of PD</kwd>
<kwd>gold standard</kwd>
<kwd>subtypes</kwd>
<kwd>disease heterogeneity</kwd>
<kwd>nonmotor prodrome</kwd>
<kwd>MDS diagnostic criteria</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Since the original description of Parkinson's disease (PD), there have been radical changes in our conceptualization of the disease, starting with a better understanding of motor manifestations, clear pathologic definitions, and availability of therapy that is so reliably effective as to be part of diagnostic criteria. Moreover, our understanding continues to develop, with increasing knowledge of nonmotor aspects, recognition that neurodegeneration can start before motor symptoms manifest, better understanding of genetics and environmental factors, and progress toward developing reliable biomarkers and animal models. With these advances, clinicians and specialists in genetics, epidemiology, pathology, and basic science have developed their own conceptualizations of disease; each valid, but none representing the whole truth. Can these conceptualizations be united under one umbrella definition?</p>
<p>To deal with the challenges of disease definition, the International Parkinson and Movement Disorder Society (MDS) convened a task force to generate an updated definition of PD. The group identified three critical issues: (1) Who decides what is PD and what is the gold standard for a “final” diagnosis? (2) What clinical features fit under the PD umbrella? Should subtypes be incorporated into the diagnosis? Should some diagnostic entities be held distinct (e.g., dementia with Lewy bodies; DLB)? (3) Defining disease onset—can PD be defined before classic motor features develop?</p>
<p>This review is intended as an introductory discussion article; it is not the final word on disease definition, but rather an opening of dialog. Each section will start by presenting conversational-style informal minivignettes (in italics) that summarize what clinicians or researchers often mention when pointing out problems with the current PD definition. Both sides of each issue are then discussed, followed by proposals for moving forward. Finally, we will discuss the need for new diagnostic criteria for PD.</p>
<sec>
<title>What Is the Gold Standard for the Definition of PD?</title>
<p>The issue:
<italic>A patient with classic clinical PD died without autopsy; can one never say they are “sure” she had PD? Why is autopsy the gold standard if it is almost never available (and might become outdated, once we have good biomarkers). Furthermore, don't genetic studies suggest that pathology can be inconclusive? A patient from a family of pathologically confirmed LRRK2 PD who meets clinical criteria for PD, but has no Lewy bodies (LB) on autopsy, or patients with parkin mutations without LB; do they not have PD?</italic>
</p>
<p>What we currently consider as the gold standard for PD diagnosis is not always explicit. Nevertheless, most clinicians would endorse the diagnostic gold standard as a combined clinical and pathological syndrome, consisting of the following:</p>
<list list-type="order">
<list-item>
<p>A motor clinical syndrome, with levodopa-responsive parkinsonism, typical clinical characteristics, and an absence of markers suggestive of other disease.</p>
</list-item>
<list-item>
<p>Pathologic confirmation of α-synuclein (α-Syn) deposition and dopamine neuronal loss in the substantia nigra pars compacta (SNpc). Only at this point is the diagnosis termed “definite.” If typical synuclein pathology is not found, the clinical diagnosis is considered incorrect. Likewise, the pathology is “incidental” in the absence of clinical symptoms or attributed to another disease if parkinsonism did not dominate the clinical picture (e.g., DLB or primary autonomic failure).</p>
</list-item>
</list>
<p>Therefore, a motor clinical syndrome is the entry point, and pathology is the arbiter of diagnosis. Pathologic findings ultimately feed back into clinical criteria by correcting clinical diagnoses.</p>
<sec>
<title>Challenging the Status Quo</title>
<p>Several challenges have been raised against the requirement for both SNpc neurodegeneration and α-Syn deposition as essential features and, more globally, of pathology's role as the ultimate arbitrator. These include the following:</p>
<list list-type="order">
<list-item>
<p>Genetic/pathologic correlation: Although, in many patients, leucine-rich repeat kinase 2 (LRRK2) mutations are associated with classic α-Syn deposition,
<xref rid="b1" ref-type="bibr">1</xref>
,
<xref rid="b2" ref-type="bibr">2</xref>
there are nonetheless reports of members of the same family having different pathologies, some without α-Syn deposition. LB are absent in 21% of G2019 mutations and >50% of non-G2019S mutations.
<xref rid="b2" ref-type="bibr">2</xref>
With
<italic>parkin</italic>
, most meet clinical PD criteria, have SN degeneration on autopsy, but have little or no α-Syn deposition
<xref rid="b2" ref-type="bibr">2</xref>
(exceptions were older and may have had coincidental “incidental LB”). We must also take into account the uncertain role of α-Syn aggregation (possibly protective) versus α-Syn oligomers (toxic) in PD pathogenesis. As a hypothetical illustration, imagine a genetic mutation that prevents aggregation of “toxic” α-Syn oligomers into “protective” LB; this mutation would recapitulate the PD pathogenic process, without α-synuclein deposition on autopsy.</p>
</list-item>
<list-item>
<p>SNpc loss is not the only pathologic feature and may not occur first: The premotor/prodromal syndrome must also have a pathologic correlate (see “The Beginning of PD” below).</p>
</list-item>
<list-item>
<p>α-Syn pathology may not determine clinical symptoms: On autopsy, approximately 15% have incidental LB, 5 times the prevalence of clinical LB diseases.
<xref rid="b3" ref-type="bibr">3</xref>
<xref rid="b6" ref-type="bibr">6</xref>
If α-Syn pathology defines disease alone, must all these patients be considered asymptomatic PD?</p>
</list-item>
<list-item>
<p>α-Syn aggregates may not be the first pathology: Lewy pathology may develop relatively late, with presynaptic dysfunction being the first abnormality.
<xref rid="b7" ref-type="bibr">7</xref>
<xref rid="b9" ref-type="bibr">9</xref>
Might current pathologic criteria miss early stages of PD?</p>
</list-item>
<list-item>
<p>Pragmatic considerations: Autopsy is performed only at the end of life (not useful diagnostically during life), and only few have pathologic confirmation.</p>
</list-item>
</list>
<p>Potential alternate gold standards for diagnosis could include the following:</p>
<list list-type="order">
<list-item>
<p>Clinical diagnosis alone: James Parkinson did not define a pathologic diagnosis, but a clinical syndrome. This clinical syndrome is readily recognized and, despite interindividual variability, very characteristic. Patients experience clinical disease, not pathology, and clinical criteria contain the features important to patients, including response to treatment.</p>
</list-item>
<list-item>
<p>Genetics: If experience with
<italic>parkin-</italic>
and LRRK2-related parkinsonism suggests that pathology can be inconclusive, can genetics ultimately define diagnosis?</p>
</list-item>
</list>
</sec>
<sec>
<title>Defending the Status Quo</title>
<p>Despite these issues, are there reasons to keep our current clinicopathologic standard?</p>
<list list-type="order">
<list-item>
<p>Alternate gold standards also have limitations:</p>
<list list-type="roman-lower">
<list-item>
<p>Clinical: Defining PD solely on a clinical basis is circular; you can never be wrong. If clinical diagnosis is the gold standard, a patient who meets clinical criteria has PD regardless of autopsy findings. What of patients with clinical PD diagnosis who have clear pathology of alternate diagnoses, such as MSA or PSP?</p>
</list-item>
<list-item>
<p>Genetics: Well under 10% of PD patients currently have a genetic explanation. Moreover, whereas new genetic causes may be defined, heritability is relatively low; most monozygotic twins are discordant.
<xref rid="b10" ref-type="bibr">10</xref>
,
<xref rid="b11" ref-type="bibr">11</xref>
Also, if genes are inpenetrant, interpreting a positive genetic test as diagnostic can be incorrect. Finally, genetic mutations may result in heterogeneous clinical phenotypes, not just heterogeneous pathology; for example, LRRK2 mutations are also associated with motor neuron disease.
<xref rid="b12" ref-type="bibr">12</xref>
If a LRRK2 carrier had classic clinical motor neuron disease, would genetic criteria mandate diagnosis of PD?</p>
</list-item>
</list>
</list-item>
<list-item>
<p>Although pragmatic considerations imply that pathological diagnosis is not useful for an individual, pathology can nonetheless serve as an ultimate reference by which clinical criteria are tested. Furthermore, if biomarkers of both α-Syn deposition and SNpc degeneration become sufficiently reliable, these could ultimately replace autopsy confirmation.</p>
</list-item>
<list-item>
<p>
<italic>Parkin</italic>
and similar mutations might have a different underlying pathogenesis than sporadic PD. Moreover, these patients often have important clinical differences (e.g., earlier age of onset). It thus might be entirely appropriate to consider them separate diseases or a subcategory of PD.</p>
</list-item>
<list-item>
<p>Finally, it should not be forgotten that the vast majority (∼95%) of patients who fulfill clinical criteria have classic α-Syn pathology. Moreover, when the clinical diagnosis is “wrong,” there is usually a clear alternate pathologic cause (PSP, MSA, and so on). If we let exceptional cases drive our definition, do we “throw out the baby with the bathwater?”</p>
</list-item>
</list>
</sec>
<sec>
<title>Moving Forward</title>
<p>
<bold>
<italic>The task force proposes</italic>
</bold>
the following:</p>
<list list-type="order">
<list-item>
<p>The core clinicopathologic criteria of a clinical motor syndrome accompanied by SNpc neurodegeneration and synuclein deposition remain a gold standard of PD diagnosis. In the future, should reliable biomarkers of synuclein deposition be developed, these can be used to indicate a likely gold-standard clinicopathologic diagnosis.</p>
</list-item>
<list-item>
<p>To incorporate genetic findings under the PD umbrella, a separate “clinicogenetic” category should be created to diagnose PD, regardless of the occurrence of synuclein deposition. This category would refer specifically to highly penetrant mutations in which the majority of affecteds meet clinical PD criteria, regardless of whether autopsy specimens of patients with this mutation find α-Syn pathology. In research studies, this diagnostic subcategory could be included or not according to the context. For example, an autopsy study validating clinical diagnostic criteria might exclude such patients, a randomized trial of symptomatic dopaminergic therapy might include them, and a neuroprotective trial may elect to include or exclude, depending upon the mechanism of the agent.</p>
</list-item>
<list-item>
<p>A new scheme is likely needed to replace the current PARK classification, which is under considerable strain. This scheme should specifically differentiate between causative genes and risk factors, consider the predominant phenotype, and—in the long run—admit the incorporation of protective variants.
<xref rid="b13" ref-type="bibr">13</xref>
A dedicated task force of the MDS is currently working on this complex issue.</p>
</list-item>
</list>
</sec>
</sec>
<sec>
<title>What Features Fit Under the PD Umbrella?</title>
<sec>
<title>DLB</title>
<p>The issue: A patient developed cognitive impairment 18 months after PD diagnosis; he has PD dementia (PDD). Another developed cognitive impairment 10 months after PD diagnosis; according to current definitions, the initial diagnosis was “wrong,” and she has DLB. Does this make sense?</p>
<p>As diagnostic criteria currently stand, dementia developing before the second year of parkinsonism is an exclusion criterion for PD; the diagnosis is DLB.
<xref rid="b14" ref-type="bibr">14</xref>
<xref rid="b16" ref-type="bibr">16</xref>
If dementia starts after 1 year, the diagnosis is PDD.</p>
</sec>
<sec>
<title>Challenging the Status Quo</title>
<p>Beyond the arbitrary nature of the 1-year rule, there is increasing controversy about whether the distinction itself is valid. Briefly, the challenges are
<xref rid="b16" ref-type="bibr">16</xref>
as follows:</p>
<list list-type="order">
<list-item>
<p>Similar dementia presentation, with hallucinations, fluctuations, neuroleptic sensitivity, and rapid eye movement sleep behavior disorder (RBD) in both.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b17" ref-type="bibr">17</xref>
</p>
</list-item>
<list-item>
<p>Similar neuropsychological findings, with predominant visuoperceptual impairment, improvement of memory with cueing, and so on.
<xref rid="b16" ref-type="bibr">16</xref>
</p>
</list-item>
<list-item>
<p>Similar nonmotor profile, with olfactory loss, depression, autonomic dysfunction, and sleep disorders in both.</p>
</list-item>
<list-item>
<p>Similar imaging, with overlapping patterns of cortical atrophy, glucose utilization, neurotransmitter changes,
<xref rid="b18" ref-type="bibr">18</xref>
and diffusion tensor imaging.
<xref rid="b19" ref-type="bibr">19</xref>
</p>
</list-item>
<list-item>
<p>Similar prodromal stage: For example, patients with idiopathic RBD develop both syndromes, with little difference in clinical evolution patterns.
<xref rid="b20" ref-type="bibr">20</xref>
</p>
</list-item>
<list-item>
<p>Similar genetics: For example, family members with α-Syn duplications or triplications as well as glucocerebrosidase mutations can present with either condition.</p>
</list-item>
<list-item>
<p>Similar pathology: Patients in both groups demonstrate α-Syn pathology in both the brainstem and cortex.</p>
</list-item>
</list>
<p>Implicit in this discussion is the conceptualization of DLB, which shares clinical and pathological features of Alzheimer's disease (AD) and PDD. This overlap has created tension in naming the condition, with evolution from “Lewy body variant of AD,” to “Lewy body dementia,” to the current “dementia with Lewy bodies.”</p>
</sec>
<sec>
<title>Defending the Status Quo</title>
<p>There are several reasons to consider retaining the current distinction:</p>
<list list-type="order">
<list-item>
<p>Although not universally specific, there are imaging differences between PDD and DLB, including degree of amyloid deposition, cholinergic loss, vascular damage, single-photon emission CT/PET hypoperfusion, and atrophy patterns.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
</p>
</list-item>
<list-item>
<p>Parkinsonism in DLB can differ from idiopathic PD, typically with less tremor and
<sc>l</sc>
-dopa response.
<xref rid="b22" ref-type="bibr">22</xref>
Many parkinsonian DLB patients would not meet criteria for clinical PD.</p>
</list-item>
<list-item>
<p>Although patients with DLB and PDD look similar at end stage, the course can be extremely different. A counterexample to the vignette: A patient diagnosed as AD with a severe amnestic disorder eventually develops visual hallucinations, cognitive fluctuations, and mild parkinsonian signs (DLB). Another patient has typical PD with normal cognition for many years and eventually develops hallucinations and cognitive decline (PDD). Are these patients not distinct?</p>
</list-item>
</list>
</sec>
<sec>
<title>Moving Forward</title>
<p>Despite the controversy, most agree that there is important clinicopathologic overlap between these conditions. Perhaps in DLB and PDD, there is a continuum between relatively “pure” α-Syn pathology and a predominant Alzheimer (± vascular) pathology (
<xref ref-type="fig" rid="fig01">Fig. 1</xref>
). Most DLB patients will develop parkinsonism and most PD patients will develop dementia, but onset time differs. At one extreme are patients with young-onset classic PD who remain dementia free for most of their long disease course; if they eventually dement, cortical pathology would be predominantly LB, with sparse AD pathology. At the other extreme are patients who first develop dementia and manifest parkinsonism very late or never during life; these patients would have more AD pathology (± vascular pathology) with less LB deposition. Between these extremes lie the majority of patients. If a continuous spectrum exists, the advantages of categorical division are debatable.</p>
<fig id="fig01" position="float">
<label>Figure 1</label>
<caption>
<p>Simplified model of how the type of cortical pathology and clinical presentation of PDD and DLB might interact. Dementia in DLB/PD is associated with two major pathologies: synucleinopathy (i.e., Parkinson pathology) and neuritic amyloidopathy (i.e., Alzheimer pathology). In PD patients who develop dementia very late in their illness, or not at all (far left), neuritic amyloid deposition is minimal (or absent), and cortical pathology is mainly that of α-Syn deposition. At the other extreme, DLB patients with predominant neuritic amyloid deposition and very minimal α-Syn deposition would usually be diagnosed as AD during life, developing clinical DLB hallmarks late (if at all). Between these two extremes of the spectrum lie the most patients with PD and DLB. This hypothetical spectrum is not meant to be exclusive—other factors may also be important in determining dementia onset (e.g., “top down” vs. “bottom up” α-Syn deposition, degree of vascular pathology, and so on).</p>
</caption>
<graphic xlink:href="mds0029-0454-f1"></graphic>
</fig>
<p>Therefore,
<bold>
<italic>the task force proposes</italic>
</bold>
the following:</p>
<p>Consider omitting the “1-year” rule, which separates PDD and DLB. Rather, when a patient presents with motor signs
<italic>and</italic>
meets full clinical criteria for PD, the diagnosis of PD is applied, regardless of presence or timing of dementia. In other words, dementia is no longer an exclusion criterion for PD. For those patients who already carry a DLB diagnosis (according to consensus criteria
<xref rid="b23" ref-type="bibr">23</xref>
), the diagnosis can optionally be qualified as “PD (DLB subtype).”</p>
<p>Note that this proposal would not invalidate the diagnostic category of DLB. In clinical communication with patients with the DLB subtype, the diagnostic term DLB could continue to be used. Moreover, the classification of patients with DLB diagnosis who do not have parkinsonism, or whose parkinsonism does not not meet PD criteria (e.g., no response to dopaminergic medications), would not be affected by this definition change.</p>
</sec>
</sec>
<sec>
<title>PD Subtypes</title>
<p>The issue: A patient had unilateral tremor onset at age 40, robust
<sc>l</sc>
-dopa response with fluctuations and, 20 years later, has few nonmotor features. A second developed bilateral bradykinesia and rigidity at age 80 and had no fluctuations, but had severe constipation, urinary dysfunction, sleep disturbance, and depression, eventually dying with dementia. Do these patients have the same disease?</p>
<sec>
<title>Challenging the Status Quo</title>
<p>PD has considerable variability in rate of progression of motor manifestations and prevalence of nonmotor manifestations. This can question the conceptualization of PD as a unitary disorder. At minimum, it suggests that PD may be divisible into subtypes. Currently, no formal subtype classification exists and subtypes have not been generally incorporated into research protocols.
<xref rid="b24" ref-type="bibr">24</xref>
</p>
<p>Most attempts to classify subtypes rely upon one of two approaches. One uses data-driven approaches with cluster analysis to identify subtypes in a hypothesis-free manner.
<xref rid="b25" ref-type="bibr">25</xref>
<xref rid="b32" ref-type="bibr">32</xref>
In these studies, clusters have been defined based on age, motor features, and, possibly, a nonmotor symptom cluster.
<xref rid="b26" ref-type="bibr">26</xref>
These variables correlate with different mortality, progression, motor complications, dementia, and behavioral symptoms. The second approach classifies subgroups on a single factor and looks for differences between groups. Two commonly suggested subtypes are onset age and tremor dominance. Age subtyping is proposed because young patients have more robust
<sc>l</sc>
-dopa response, more motor complications, and fewer cognitive disturbances.
<xref rid="b33" ref-type="bibr">33</xref>
<xref rid="b35" ref-type="bibr">35</xref>
Tremor-predominant subtypes are proposed because they may have better prognosis and fewer cognitive disturbances.
<xref rid="b33" ref-type="bibr">33</xref>
<xref rid="b35" ref-type="bibr">35</xref>
Other studies suggest other potential subtype identifiers; for example, olfactory loss correlates with cognitive impairment,
<xref rid="b36" ref-type="bibr">36</xref>
and RBD correlates with autonomic dysfunction and higher dementia risk.
<xref rid="b37" ref-type="bibr">37</xref>
,
<xref rid="b38" ref-type="bibr">38</xref>
In the future, it may also be possible to subdivide PD according to pathogenic mechanism (mitochondrial predominant, inflammatory predominant, and so on).</p>
</sec>
<sec>
<title>Defending the Status Quo</title>
<list list-type="order">
<list-item>
<p>Regardless of the dramatic differences in clinical manifestations, most patients with PD have a characteristic pathologic substrate, suggesting that a unifying diagnosis is appropriate. Moreover, many other diseases have dramatic differences in clinical severity and manifestations.</p>
</list-item>
<list-item>
<p>Current subtypes may not impact much upon disease course. Some studies find that tremor has little effect on prognosis.
<xref rid="b32" ref-type="bibr">32</xref>
,
<xref rid="b34" ref-type="bibr">34</xref>
Where there are differences, there are potential confounds, including diagnostic sensitivity (tremor-dominant patients are diagnosed earlier, so prognosis appears better for disease duration), or misdiagnosis (patients misdiagnosed as tremor-predominant PD have relatively benign alternate diagnoses, such as essential tremor, versus akinetic-rigid syndrome alternate diagnoses, such as MSA or PSP). Age is continuous, and defining robust cutoffs is not simple. For example, young cutoffs (e.g., <40) help identify genetic mutations, but represent only a small proportion of PD patients (<1%).
<xref rid="b39" ref-type="bibr">39</xref>
,
<xref rid="b40" ref-type="bibr">40</xref>
Criteria for “old-onset” PD may also be needed, because older patients have worse prognosis, higher mortality, more dementia, and more mixed pathology. Finally, current age, rather than onset age, may be the critical factor influencing disease manifestations.</p>
</list-item>
</list>
</sec>
<sec>
<title>Moving Forward</title>
<p>In summary, there is no doubt that PD has considerable heterogeneity in clinical presentation and prognosis.
<bold>
<italic>The task force proposes</italic>
</bold>
the following:</p>
<list list-type="order">
<list-item>
<p>Clinical subtypes should only be delineated if there are clear data that demonstrate consistent, large differences in prognosis, predicted disease manifestations, or treatment. Currently, it is unclear whether any of the current subtype classifications qualify.</p>
</list-item>
<list-item>
<p>The search for subtypes should not be restricted to clinical features, but should include subtypes of molecular pathogenesis.</p>
</list-item>
</list>
</sec>
</sec>
<sec>
<title>The Beginning of PD</title>
<p>The issue: A patient has RBD, olfactory loss, constipation, and depression, but no parkinsonism. Dopaminergic neuroimaging and SN ultrasound are abnormal. Doesn't this patient have PD?</p>
<sec>
<title>Challenging the Status Quo</title>
<p>It has become clear that neurodegeneration in PD likely begins years or decades before full PD diagnosis can be made.
<xref rid="b41" ref-type="bibr">41</xref>
In this phase, nonmotor manifestations, such as RBD, hyposmia, autonomic dysfunction, visual disturbances, and depression, often occur. This has important implications for defining PD. The patient described above almost certainly has neurodegeneration with α-Syn pathology and therefore, in some sense, “has” PD. If so, should our definition be changed?</p>
</sec>
<sec>
<title>Defending the Status Quo</title>
<p>Before adding early stages to a formal PD definition, the following caveats should be noted:</p>
<list list-type="order">
<list-item>
<p>Autopsy studies find incidental LB disease in 15% of the elderly, but only a minority manifest clinical symptoms. This suggests that there may be compensatory mechanisms that forestall progression, so transition to clinical PD may not be inevitable.</p>
</list-item>
<list-item>
<p>Most premotor signs are nonspecific (e.g., olfactory dysfunction,
<xref rid="b42" ref-type="bibr">42</xref>
constipation,
<xref rid="b43" ref-type="bibr">43</xref>
and SN hyperechogenicity
<xref rid="b44" ref-type="bibr">44</xref>
), reducing accuracy of early diagnosis.</p>
</list-item>
<list-item>
<p>Neurodegeneration in PD may not universally start outside the SNpc. Moreover, not all PD patients have nonmotor features, especially in early motor stages.</p>
</list-item>
<list-item>
<p>Given that PD definition has always centered on a motor syndrome, changing the definition to include patients without motor signs is a major shift. It would radically change communication with patients, estimates of disease prevalence, and so on. For continuity with historical standards, it may be preferable to retain the motor syndrome in “classic” PD diagnosis and delineate prodromal stages separately.</p>
</list-item>
</list>
</sec>
<sec>
<title>Moving Forward</title>
<p>Regardless of the caveats listed above, there is little question that many patients have a preclinical/prodromal stage of their disease, which should be incorporated in the definition of PD.
<xref rid="b45" ref-type="bibr">45</xref>
,
<xref rid="b46" ref-type="bibr">46</xref>
<bold>
<italic>The task force proposes</italic>
</bold>
the following:</p>
<list list-type="order">
<list-item>
<p>Clinical diagnosis of classic PD should remain centered on a motor syndrome. Separate research-based criteria should be developed to allow diagnosis of early PD stages.</p>
</list-item>
<list-item>
<p>For delineation of early stages, disease should be classified as “preclinical” and “prodromal.” Preclinical refers to the presence of neurodegenerative synucleinopathy without clinical symptoms (i.e., defined by biomarkers; note that this stage cannot be currently diagnosed because reliable biomarkers are not available). Prodromal refers to the presence of early symptoms and signs before the classical PD diagnosis is possible. This prodromal term makes no assumptions about the order in which motor versus nonmotor symptoms develop.</p>
</list-item>
<list-item>
<p>Because one cannot determine whether any patient with prodromal neurodegenerative synucleinopathy will eventually progress to full clinical PD, the definition of prodromal PD should center upon the likelihood of a neurodegenerative synucleinopathy being present, regardless of “conversion rate” to full clinical PD.</p>
</list-item>
<list-item>
<p>Although PD, by definition, passes inevitably through some type of prodromal phase, there are currently no 100% reliable means to identify prodromal PD. Therefore, diagnostic criteria for prodromal PD will necessarily be probabilistic. We propose two levels of certainty. Probable prodromal PD would refer to a high likelihood (e.g., >80%; sufficiently certain for neuroprotective trials). Possible prodromal PD would refer to a lower, but still substantial, likelihood of neurodegenerative synucleinopathy (e.g., 30%-80%).</p>
</list-item>
<list-item>
<p>Prodromal PD criteria should incorporate clinical motor markers, clinical nonmotor markers, and nonclinical biomarkers. Inclusion of a marker into prodromal criteria should generally require prospective studies documenting predictive value for full clinical PD. Markers should be divided into categories of specificity, such that high specificity markers carry more weight than those with lower specificity. Criteria should also incorporate risk, adjusting probability estimates for persons with documented high-risk states (e.g., carriers of genetic mutations).</p>
</list-item>
</list>
</sec>
</sec>
<sec>
<title>From Definition to Diagnostic Criteria</title>
<p>When a disease definition changes, its diagnosis inevitably changes with it. Therefore, creation of a new definition provides an opportunity to develop new clinical diagnostic criteria. There are several reasons to develop new clinical diagnostic criteria:</p>
<list list-type="order">
<list-item>
<p>No standard clinical criteria exist. Many criteria have been proposed for PD,
<xref rid="b45" ref-type="bibr">45</xref>
<xref rid="b52" ref-type="bibr">52</xref>
but none have been developed or adopted by an international organization such as the MDS.</p>
</list-item>
<list-item>
<p>New knowledge: Diagnostic criteria must accommodate new findings. For example, it is no longer appropriate to consider having affected family members or autonomic dysfunction as exclusion criteria.
<xref rid="b46" ref-type="bibr">46</xref>
,
<xref rid="b53" ref-type="bibr">53</xref>
Moreover, the systemic character of the disease needs to be acknowledged, especially incorporating nonmotor symptoms.
<xref rid="b54" ref-type="bibr">54</xref>
</p>
</list-item>
<list-item>
<p>Changes in health care or disease patterns: Exclusion criteria for patients taking neuroleptic medications
<xref rid="b45" ref-type="bibr">45</xref>
require rewording, given development of atypical neuroleptics such as clozapine and quetiapine. Similarly, excluding patients with encephalitis lethargica
<xref rid="b47" ref-type="bibr">47</xref>
,
<xref rid="b55" ref-type="bibr">55</xref>
may not be relevant as this epidemic passes into history.</p>
</list-item>
<list-item>
<p>Changes in definition that change diagnosis: For example, if early dementia is permitted, exclusion criteria targeted at cognitive impairment would be removed.</p>
</list-item>
</list>
<p>How then might future diagnostic criteria look? In developing criteria, some key aspects must be considered:</p>
<list list-type="order">
<list-item>
<p>Clear definition of the motor syndrome: If the motor syndrome remains central to diagnosis, parkinsonism itself must be clearly defined. Several large-scale studies have documented mild parkinsonian syndromes in 25% to 50% of elderly persons without clinical features of PD
<xref rid="b56" ref-type="bibr">56</xref>
<xref rid="b59" ref-type="bibr">59</xref>
or α-Syn deposition
<xref rid="b57" ref-type="bibr">57</xref>
,
<xref rid="b60" ref-type="bibr">60</xref>
; these must be distinguished from PD. Moreover, thresholds must be delineated to define parkinsonism “conversion” from prodromal stages.</p>
</list-item>
<list-item>
<p>Clinical expert as benchmark: 75% to 95% of patients diagnosed by experts during life have PD confirmed on autopsy, and more recent studies usually find better accuracy.
<xref rid="b55" ref-type="bibr">55</xref>
,
<xref rid="b61" ref-type="bibr">61</xref>
,
<xref rid="b62" ref-type="bibr">62</xref>
Of note, experienced clinicians may diagnose PD with even greater accuracy than formal diagnostic criteria, perhaps because clinicians interpret exclusion criteria in context.
<xref rid="b61" ref-type="bibr">61</xref>
,
<xref rid="b63" ref-type="bibr">63</xref>
If clinical expert opinion is the gold-standard diagnostic technique in life, then diagnostic criteria should attempt to codify the diagnostic process of an expert clinician. Criteria should systematize this process, so that it can be reproducible between clinicians (essential in research studies) and applied by clinicians with less expertise.</p>
</list-item>
<list-item>
<p>Diversity of criteria types: Imitating the diagnostic process of an experienced clinician involves incorporating numerous factors. First, clinicians assess both negative features that argue against PD and positive features that argue for PD. Second, not all features are of equal weight. Some negative features are so specific that they are incompatible with PD. Other features suggest a possible alternate cause, but are insufficient by themselves to preclude diagnosis. Third, rather than following a “recipe” to make diagnoses, experienced clinicians allow for flexibility in application of exclusion criteria, particularly if there are clear extenuating circumstances or complex situations that alter the significance of a criterion.</p>
</list-item>
<list-item>
<p>Time: Diagnostic accuracy increases with time; early in disease progression, response to treatment is less defined, and hallmarks of other neurodegenerative diseases may not have emerged. Also, some “atypical” features are incompatible with diagnosis early in disease, but may be a late feature in otherwise typical PD.</p>
</list-item>
<list-item>
<p>Grades of certainty: Overemphasis on avoiding false-positive diagnoses means missing many patients with true disease, whereas overemphasis on detecting all PD patients leads to false-positive diagnoses. The importance of false negatives versus false positives varies according to the purpose for which criteria are applied. For example, in a randomized, clinical trial, ensuring high specificity of PD diagnosis is key, and incorrect exclusion of true PD cases is arguably less critical (although excessive exclusion creates generalizability bias). By contrast, for natural history studies and epidemiologic research, diagnostic specificity and generalizability are both critical; one must balance false positives and false negatives.</p>
</list-item>
<list-item>
<p>Ancillary testing: Currently, PD diagnoses are generally made clinically, without requiring additional diagnostic tests. Any criteria should be applicable across a broad range of settings, and demanding specific ancillary diagnostic testing reduces generalizability and utility of the criteria. However, in certain contexts, ancillary diagnostic testing is used, particularly in resolving uncertain cases. Moreover, as knowledge advances, diagnostic biochemical markers, neuroimaging, or means to document α-Syn deposition may become clinically available.</p>
</list-item>
</list>
<p>Therefore
<bold>
<italic>the task force proposes</italic>
</bold>
the following:</p>
<list list-type="order">
<list-item>
<p>Formal MDS diagnostic criteria should be created for the diagnosis of clinical PD.</p>
</list-item>
<list-item>
<p>Parkinsonism should remain a core feature of PD, based upon a combination of cardinal manifestations. The criteria should include clear definitions of what constitutes each cardinal manifestation, including explicit instructions for examination.</p>
</list-item>
<list-item>
<p>The benchmark of diagnostic criteria should be the expert clinical examination.</p>
</list-item>
<list-item>
<p>Criteria should incorporate both negative features (that argue against diagnosis) and positive features (that argue for diagnosis).</p>
</list-item>
<list-item>
<p>Criteria should be weighted, so that features that are highly specific for alternate conditions are differentiated from less specific “red flags.”</p>
</list-item>
<list-item>
<p>Criteria should incorporate a time component, such that certainty can increase with longer disease duration, and individual diagnostic criteria can be applied differentially in early versus late disease.</p>
</list-item>
<list-item>
<p>Criteria should incorporate different levels of certainty, delineated as “clinical PD” (highly specific, but not necessarily sensitive or representative) and “possible PD” (balancing specificity and sensitivity).</p>
</list-item>
<list-item>
<p>Although ancillary diagnostic tests can be incorporated, only tests that have been extensively proven as specific diagnostic markers in PD should be included. Moreover, they should be considered as ancillary only and not be essential to making diagnosis.</p>
</list-item>
</list>
</sec>
<sec sec-type="conclusions">
<title>Conclusion</title>
<p>In summary, advances in the field of PD have strained our current definition of PD. This article is meant to introduce the issue of PD redefinition and provide preliminary proposals for how to advance. Before the MDS task force creates formal diagnostic criteria, we would like to enlist the input of our members. To be part of the process, please visit the MDS website and offer your ideas and feedback.</p>
</sec>
</body>
<back>
<sec>
<title>Author Roles</title>
<p>(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique.</p>
</sec>
<sec>
<title>Financial Disclosures</title>
<p>This manuscript is a statement of the MDS Task Force on the Definition of Parkinson's Disease. It summarizes the conclusion of multiple discussions on different aspects of PD diagnosis. All Task Force members have been involved in the discussions.</p>
<p>Daniela Berg and Ron Postuma designed the manuscript and wrote the first draft (A).</p>
<p>Bastiaan Bloem, Piu Chan, Bruno Dubois, Thomas Gasser, Christopher G. Goetz, Glenda M. Halliday, John Hardy, Anthony E. Lang, Irene Litvan, Kenneth Marek, José Obeso, Wolfgang Oertel, C. Warren Olanow, Werner Poewe, Matthew Stern and Günther Deuschl all reviewed the manuscript and provided helpful critique which was implemented by Daniela Berg and Ron Postuma (B).</p>
<p>Author: Daniela Berg, MD</p>
<p>Affiliation: University of Tuebingen, Centre for Neurology, Dept. of Neurodegeneration, Hertie Institute for Clinical Brain Research and German Centre for Neurodegenerative Diseases (DZNE)</p>
<p>Consultancies/Advisory Boards: UCB Pharma, Novartis</p>
<p>Honoraria/Participation in a company sponsored speaker's bureau: UCB Pharma, GlaxoSmithKline, TEVA Pharma, Lundbeck</p>
<p>Grants: Michael J. Fox Foundation, Janssen Pharmaceutica, UCB Pharma, Boehringer Ingelheim, Internationale Parkinson Fonds, German Parkinson's Disease Association (dPV), TEVA</p>
<p>Author: Ron Postuma, MD, MSc</p>
<p>Affiliation: Montreal General HospitalConsultant: Teva Neurosciences</p>
<p>Honoraria: Teva Neurosciences, Novartis Canada (speaker fees)</p>
<p>Author: Bastiaan R. Bloem, MD, PhD</p>
<p>Affiliation: Radboud University Nijmegen Medical Center</p>
<p>Consultant: UCB, Danone, Prinses Beatrix Fonds, Strichting Interationaal Parkinson Fonds</p>
<p>Grants: Stichting Parkinson Nederland, ZonMw, Michael J Fox Foundation</p>
<p>Author: Piu Chan, MD, PhD</p>
<p>Affiliation: Xuanwu Hospital of Capitol of Medical Sci.</p>
<p>Author: Bruno Dubois, MD, PhD</p>
<p>Affiliation: Hospital De La Salpetriere</p>
<p>Consultant: Eli Lilly – Affiris</p>
<p>Author: Thomas Gasser, MD</p>
<p>Affiliation: Neurology University – Klinik</p>
<p>Consultant: Cephalon</p>
<p>Grants: Novartis, Teva, Boehringer-Ingelheim</p>
<p>Honoraria: Boehringer-Ingelheim, Schwarz Pharma, Valeant</p>
<p>Author: Christopher G. Goetz, MD</p>
<p>Affiliation: Rush University Medical Center</p>
<p>Consultant: Consulting and Advisory Board Membership with honoraria: AOP Orphan, Addex Pharma, Advanced Studies of Medicine, Boston Scientific, CHDI, Health Advances, ICON Clinical Research, Ingenix (i3 Research), National Institutes of Health, Neurocrine, Oxford Biomedica, Synthonics.</p>
<p>Grants: Funding from NIH, Michael J. Fox Foundation, Dr. Goetz directs the Rush Parkinson's Disease Research Center that receives support from the Parkinson's Disease Foundation. He directs the translation program for the MDS-UPDRS and UDysRS and receives funds from the International Parkinson and Movement Disorder Society for this effort</p>
<p>Honoraria: International Parkinson and Movement Disorder Society, American Academy of Neurology, University of Pennsylvania, University of Michigan, University of Chicago, University of Luxembourg</p>
<p>Royalty: Oxford University Press, Elsevier Publishers, Wolters Kluwer Health, Lippincott, Wilkins and Williams</p>
<p>Salary: Rush University Medical Center</p>
<p>Author: Glenda M. Halliday, PhD</p>
<p>Affiliation: Neuroscience Research, Australia</p>
<p>Grants: National Health & Medical Research Council of Australia project grants, Michael J Fox Foundation and Shake-it-up Australia.</p>
<p>Honoraria: MDS, MDPD, WFN World Congress on PD, Dopamine2013, AAIC, International frontotemporal dementia meetings, International alpha-synuclein meeting, Universidad de Navarra, Lund University, University of Queensland, Van Andel Institute</p>
<p>Ownership Interest: Chochlear, NIB Holdings</p>
<p>Royalty: Elsevier Publishing</p>
<p>Salary: University of New South Wales, National Health and Medical Research Council of Australia</p>
<p>Author: John A. Hardy, MD</p>
<p>Affiliation: UCL Institute of Neurology</p>
<p>Consultant: Eli Lilly, Johnon & Johnson, Eisai</p>
<p>Author: Anthony E. Lang, OC, MD, FRCPC</p>
<p>Affiliation: Toronto Western Hospital</p>
<p>Consultant: Abbott, Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boerhinger-Ingelheim, Ceregene, Medtronic, Merck, Novartis, NeuroPhage Pharmaceuticals, and Teva.</p>
<p>Grants: Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Parkinson Society Canada, Tourette Syndrome Association, W. Garfield Weston Foundation.</p>
<p>Honoraria: Teva</p>
<p>Royalty: Saunders, Wiley-Blackwell, Johns Hopkins Press, Cambridge University Press</p>
<p>Author: Irene Litvan, MD</p>
<p>Affiliation: Movement Disorder Center, UC San Diego</p>
<p>Member: Pfizer and Abbvie Advisory Boards</p>
<p>Consultant: Novartis and Biotie</p>
<p>Research awards: National Institutes of Aging 5R01AG024040, CurePSP and CBD Solutions</p>
<p>Author: Kenneth Marek, MD</p>
<p>Affiliation: Institute for Neurodegenerative Disorders</p>
<p>Consultant: Novartis, Lilly, GE Healthcare, Piramal, Prothena, Roche, EMD Serono, Merck, nLIfe</p>
<p>Grants: Novartis, Lilly, GE Health, Serono, Merck</p>
<p>Ownership Interest: Equity inter</p>
<p>Author: Jose Obeso, MD, PhD</p>
<p>Affiliation: University of Navarra</p>
<p>Consultant: Has served in the Advisory Board of GSK (UK), and received honorarium for lecturing in meetings organized by GSK (Spain), Lundbeck-TEVA and UCB.</p>
<p>Grants: Funding from Spanish Science and Education Ministery and European Union (REPLACES)</p>
<p>Salary: University of Navarra</p>
<p>Author: Wolfgang H. Oertel, MD</p>
<p>Affiliation: Philipps University of Marburg</p>
<p>Consultant: Novartis, Boehringer-Ingelheim, UCB, Teva, Orion, Merck-Sharp&Dohme</p>
<p>Grants: UCB, Teva</p>
<p>Honoraria: Novartis, Boehringer-Ingelheim, UCB, Teva, Orion, Desitin, Bayer Schering, Merck-Sharp&Dohme</p>
<p>Ownership Interest: Roche</p>
<p>Author: C. Warren Olanow, MD, FRCPC</p>
<p>Affiliation: The Mount Sinai Hospital</p>
<p>Consultant: Novartis/Orion, Teva/Lundbeck, Impax, Abbott, Ceregene, Newron</p>
<p>Ownership Interest: Ceregene, Clintrex</p>
<p>Stocks: Clintrex (consults with biotie, phytopharm, civitas, pharm 2B, medivation, synagile, stem cell medicine)</p>
<p>Author: Werner Poewe, MD</p>
<p>Affiliation: Innsbruck Medical University, Department of Neurology Werner Poewe has received consultancy and lecture fees from Abbott, Astra Zeneca, Teva, Novartis, GSK, Boehringer-Ingelheim, UCB, Orion Pharma, Merck Serono and Merz in relation to clinical drug development programmes for PD.</p>
<p>Royalty: Parkinson-Syndrome und andere Bewegungsstarungen Hrsg. Oertel W, Deuschl G, Poewe W, Thiema 2011 Non-motor symptoms of Parkinson's Disease. ed. KR Chaudhuri, E. Tolosa, A. Schapira, W. Poewe, Oxford University Press, 2009 Therapeutics of Parkinson's Disease and Other Movement Disorders, ed. M. Hallett, W. Poewe, Wiley-Blackwell, 2008</p>
<p>Author: Matthew Stern, MD</p>
<p>Affiliation: Penn Neurological Institute</p>
<p>Consultant: Merz, TEVA, Cevitas, Adamas, Accorda</p>
<p>Honoraria: International Parkinson and Movement Disorder Society</p>
<p>Salary: University of Pennsylvania</p>
<p>Author: Guenther Deuschl, MD</p>
<p>Affiliation: Christian-Albrechts-University</p>
<p>Consultant: TEVA, Medtronic, Novartis, Sapiens, Medtronic</p>
<p>Grants: German Research Council, German Ministry of Education and Research, Medtronic.</p>
<p>Honoraria: TEVA, Lundbeck, Medtronic, Desitin, Medtronic</p>
<p>Royalty: Thieme Publishers</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wider</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Wszolek</surname>
<given-names>ZK</given-names>
</name>
</person-group>
<article-title>Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation</article-title>
<source>Neurodegener Dis</source>
<year>2010</year>
<volume>7</volume>
<fpage>175</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="pmid">20197701</pub-id>
</element-citation>
</ref>
<ref id="b2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulopoulos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Alcalay</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>The neuropathology of genetic Parkinson's disease</article-title>
<source>Mov Disord</source>
<year>2012</year>
<volume>27</volume>
<fpage>831</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="pmid">22451330</pub-id>
</element-citation>
</ref>
<ref id="b3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beach</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>LI</given-names>
</name>
</person-group>
<article-title>Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders</article-title>
<source>Acta Neuropathol</source>
<year>2010</year>
<volume>119</volume>
<fpage>689</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="pmid">20306269</pub-id>
</element-citation>
</ref>
<ref id="b4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parkkinen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pirttila</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Alafuzoff</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance</article-title>
<source>Acta Neuropathol</source>
<year>2008</year>
<volume>115</volume>
<fpage>399</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">18297293</pub-id>
</element-citation>
</ref>
<ref id="b5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Fujishiro</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Delledonne</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease</article-title>
<source>Acta Neuropathol</source>
<year>2008</year>
<volume>115</volume>
<fpage>437</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="pmid">18264713</pub-id>
</element-citation>
</ref>
<ref id="b6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Del Tredici</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rub</surname>
<given-names>U</given-names>
</name>
<name>
<surname>de Vos</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Jansen Steur</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Staging of brain pathology related to sporadic Parkinson's disease</article-title>
<source>Neurobiol Aging</source>
<year>2003</year>
<volume>24</volume>
<fpage>197</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="pmid">12498954</pub-id>
</element-citation>
</ref>
<ref id="b7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orimo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Uchihara</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease</article-title>
<source>Brain Pathol</source>
<year>2007</year>
<volume>17</volume>
<fpage>24</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">17493034</pub-id>
</element-citation>
</ref>
<ref id="b8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milber</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Noorigian</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Morley</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease</article-title>
<source>Neurology</source>
<year>2012</year>
<volume>79</volume>
<fpage>2307</fpage>
<lpage>2314</lpage>
<pub-id pub-id-type="pmid">23152586</pub-id>
</element-citation>
</ref>
<ref id="b9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Ulane</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Clinical progression in Parkinson disease and the neurobiology of axons</article-title>
<source>Ann Neurol</source>
<year>2010</year>
<volume>67</volume>
<fpage>715</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="pmid">20517933</pub-id>
</element-citation>
</ref>
<ref id="b10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wirdefeldt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gatz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schalling</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>NL</given-names>
</name>
</person-group>
<article-title>No evidence for heritability of Parkinson disease in Swedish twins</article-title>
<source>Neurology</source>
<year>2004</year>
<volume>63</volume>
<fpage>305</fpage>
<lpage>311</lpage>
<pub-id pub-id-type="pmid">15277625</pub-id>
</element-citation>
</ref>
<ref id="b11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanner</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies</article-title>
<source>Adv Neurol</source>
<year>2003</year>
<volume>91</volume>
<fpage>133</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="pmid">12442672</pub-id>
</element-citation>
</ref>
<ref id="b12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimprich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Biskup</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leitner</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</article-title>
<source>Neuron</source>
<year>2004</year>
<volume>44</volume>
<fpage>601</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="pmid">15541309</pub-id>
</element-citation>
</ref>
<ref id="b13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marras</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples</article-title>
<source>Neurology</source>
<year>2012</year>
<volume>78</volume>
<fpage>1016</fpage>
<lpage>1024</lpage>
<pub-id pub-id-type="pmid">22454269</pub-id>
</element-citation>
</ref>
<ref id="b14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKeith</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Commentary: DLB and PDD: the same or different? Is there a debate?</article-title>
<source>Int Psychogeriatr</source>
<year>2009</year>
<volume>21</volume>
<fpage>220</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="pmid">19173763</pub-id>
</element-citation>
</ref>
<ref id="b15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Burn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force</article-title>
<source>Mov Disord</source>
<year>2007</year>
<volume>22</volume>
<fpage>2314</fpage>
<lpage>2324</lpage>
<pub-id pub-id-type="pmid">18098298</pub-id>
</element-citation>
</ref>
<ref id="b16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lippa</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Duda</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers</article-title>
<source>Neurology</source>
<year>2007</year>
<volume>68</volume>
<fpage>812</fpage>
<lpage>819</lpage>
<pub-id pub-id-type="pmid">17353469</pub-id>
</element-citation>
</ref>
<ref id="b17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dugger</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Boeve</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies</article-title>
<source>Mov Disord</source>
<year>2012</year>
<volume>27</volume>
<fpage>72</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">22038951</pub-id>
</element-citation>
</ref>
<ref id="b18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Eggers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kalbe</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo</article-title>
<source>Neurology</source>
<year>2010</year>
<volume>74</volume>
<fpage>885</fpage>
<lpage>892</lpage>
<pub-id pub-id-type="pmid">20181924</pub-id>
</element-citation>
</ref>
<ref id="b19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Blamire</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Colloby</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Characterizing dementia with Lewy bodies by means of diffusion tensor imaging</article-title>
<source>Neurology</source>
<year>2012</year>
<volume>79</volume>
<fpage>906</fpage>
<lpage>914</lpage>
<pub-id pub-id-type="pmid">22895591</pub-id>
</element-citation>
</ref>
<ref id="b20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Postuma</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Vendette</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Montplaisir</surname>
<given-names>JY</given-names>
</name>
</person-group>
<article-title>Idiopathic REM sleep behavior disorder in the transition to degenerative disease</article-title>
<source>Mov Disord</source>
<year>2009</year>
<volume>24</volume>
<fpage>2225</fpage>
<lpage>2232</lpage>
<pub-id pub-id-type="pmid">19768814</pub-id>
</element-citation>
</ref>
<ref id="b21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johansen</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>White</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Sando</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Aasly</surname>
<given-names>JO</given-names>
</name>
</person-group>
<article-title>Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies</article-title>
<source>Parkinsonism Relat Disord</source>
<year>2010</year>
<volume>16</volume>
<fpage>307</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="pmid">20338799</pub-id>
</element-citation>
</ref>
<ref id="b22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Brandabur</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanfilippo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stebbins</surname>
<given-names>GT</given-names>
</name>
</person-group>
<article-title>Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies</article-title>
<source>Mov Disord</source>
<year>2008</year>
<volume>23</volume>
<fpage>2248</fpage>
<lpage>2250</lpage>
<pub-id pub-id-type="pmid">18823039</pub-id>
</element-citation>
</ref>
<ref id="b23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKeith</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium</article-title>
<source>Neurology</source>
<year>2005</year>
<volume>65</volume>
<fpage>1863</fpage>
<lpage>1872</lpage>
<pub-id pub-id-type="pmid">16237129</pub-id>
</element-citation>
</ref>
<ref id="b24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marras</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Parkinson's disease subtypes: lost in translation?</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>2013</year>
<volume>84</volume>
<fpage>409</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="pmid">22952329</pub-id>
</element-citation>
</ref>
<ref id="b25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Rooden</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Colas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Martinez-Martin</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Clinical subtypes of Parkinson's disease</article-title>
<source>Mov Disord</source>
<year>2011</year>
<volume>26</volume>
<fpage>51</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">21322019</pub-id>
</element-citation>
</ref>
<ref id="b26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Rooden</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Heiser</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Verbaan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Hilten</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Marinus</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The identification of Parkinson's disease subtypes using cluster analysis: a systematic review</article-title>
<source>Mov Disord</source>
<year>2010</year>
<volume>25</volume>
<fpage>969</fpage>
<lpage>978</lpage>
<pub-id pub-id-type="pmid">20535823</pub-id>
</element-citation>
</ref>
<ref id="b27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reijnders</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Ehrt</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Lousberg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leentjens</surname>
<given-names>AF</given-names>
</name>
</person-group>
<article-title>The association between motor subtypes and psychopathology in Parkinson's disease</article-title>
<source>Parkinsonism Relat Disord</source>
<year>2009</year>
<volume>15</volume>
<fpage>379</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="pmid">18977165</pub-id>
</element-citation>
</ref>
<ref id="b28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Post</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Speelman</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Clinical heterogeneity in newly diagnosed Parkinson's disease</article-title>
<source>J Neurol</source>
<year>2008</year>
<volume>255</volume>
<fpage>716</fpage>
<lpage>722</lpage>
<pub-id pub-id-type="pmid">18344057</pub-id>
</element-citation>
</ref>
<ref id="b29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Foltynie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach</article-title>
<source>J Neurol NeurosurgPsychiatry</source>
<year>2005</year>
<volume>76</volume>
<fpage>343</fpage>
<lpage>348</lpage>
</element-citation>
</ref>
<ref id="b30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graham</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sagar</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes</article-title>
<source>Mov Disord</source>
<year>1999</year>
<volume>14</volume>
<fpage>10</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">9918339</pub-id>
</element-citation>
</ref>
<ref id="b31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrag</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Ben-Shlomo</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Heterogeneity of Parkinson's disease</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>2006</year>
<volume>77</volume>
<fpage>275</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">16421140</pub-id>
</element-citation>
</ref>
<ref id="b32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selikhova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Kempster</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Revesz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>A clinico-pathological study of subtypes in Parkinson's disease</article-title>
<source>Brain</source>
<year>2009</year>
<volume>132</volume>
<fpage>2947</fpage>
<lpage>2957</lpage>
<pub-id pub-id-type="pmid">19759203</pub-id>
</element-citation>
</ref>
<ref id="b33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suchowersky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Reich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perlmutter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zesiewicz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gronseth</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</article-title>
<source>Neurology</source>
<year>2006</year>
<volume>66</volume>
<fpage>968</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="pmid">16606907</pub-id>
</element-citation>
</ref>
<ref id="b34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marras</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rochon</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Predicting motor decline and disability in Parkinson disease: a systematic review</article-title>
<source>Mov Disord</source>
<year>2002</year>
<volume>59</volume>
<fpage>1724</fpage>
<lpage>1728</lpage>
</element-citation>
</ref>
<ref id="b35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Post</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Merkus</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Speelman</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Prognostic factors for the progression of Parkinson's disease: a systematic review</article-title>
<source>Mov Disord</source>
<year>2007</year>
<volume>22</volume>
<fpage>1839</fpage>
<lpage>1851; quiz, 988</lpage>
<pub-id pub-id-type="pmid">17595026</pub-id>
</element-citation>
</ref>
<ref id="b36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bohnen</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Kotagal</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease</article-title>
<source>Brain</source>
<year>2010</year>
<volume>133</volume>
<fpage>1747</fpage>
<lpage>1754</lpage>
<pub-id pub-id-type="pmid">20413575</pub-id>
</element-citation>
</ref>
<ref id="b37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Postuma</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Montplaisir</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study</article-title>
<source>Mov Disord</source>
<year>2012</year>
<volume>27</volume>
<fpage>720</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="pmid">22322798</pub-id>
</element-citation>
</ref>
<ref id="b38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romenets</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Latreille</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease</article-title>
<source>Mov Disord</source>
<year>2012</year>
<volume>27</volume>
<fpage>996</fpage>
<lpage>1003</lpage>
<pub-id pub-id-type="pmid">22733427</pub-id>
</element-citation>
</ref>
<ref id="b39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wickremaratchi</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>D</given-names>
</name>
<name>
<surname>O'Loghlen</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>2009</year>
<volume>80</volume>
<fpage>805</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="pmid">19531689</pub-id>
</element-citation>
</ref>
<ref id="b40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Den Eeden</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Tanner</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity</article-title>
<source>Am J Epidemiol</source>
<year>2003</year>
<volume>157</volume>
<fpage>1015</fpage>
<lpage>1122</lpage>
<pub-id pub-id-type="pmid">12777365</pub-id>
</element-citation>
</ref>
<ref id="b41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Del</surname>
<given-names>TK</given-names>
</name>
</person-group>
<article-title>Invited article: Nervous system pathology in sporadic Parkinson disease</article-title>
<source>Neurology</source>
<year>2008</year>
<volume>70</volume>
<fpage>1916</fpage>
<lpage>1925</lpage>
<pub-id pub-id-type="pmid">18474848</pub-id>
</element-citation>
</ref>
<ref id="b42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Petrovitch</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Association of olfactory dysfunction with risk for future Parkinson's disease</article-title>
<source>AnnNeurol</source>
<year>2008</year>
<volume>63</volume>
<fpage>167</fpage>
<lpage>173</lpage>
</element-citation>
</ref>
<ref id="b43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbott</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Petrovitch</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Bowel movement frequency in late-life and incidental Lewy bodies</article-title>
<source>Mov Disord</source>
<year>2007</year>
<volume>22</volume>
<fpage>1581</fpage>
<lpage>1586</lpage>
<pub-id pub-id-type="pmid">17523195</pub-id>
</element-citation>
</ref>
<ref id="b44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Seppi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Behnke</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons</article-title>
<source>Arch Neurol</source>
<year>2011</year>
<volume>68</volume>
<fpage>932</fpage>
<lpage>937</lpage>
<pub-id pub-id-type="pmid">21747034</pub-id>
</element-citation>
</ref>
<ref id="b45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibb</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>1988</year>
<volume>51</volume>
<fpage>745</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="pmid">2841426</pub-id>
</element-citation>
</ref>
<ref id="b46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gelb</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gilman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Diagnostic criteria for Parkinson disease</article-title>
<source>Arch Neurol</source>
<year>1999</year>
<volume>56</volume>
<fpage>33</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">9923759</pub-id>
</element-citation>
</ref>
<ref id="b47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koller</surname>
<given-names>WC</given-names>
</name>
</person-group>
<article-title>How accurately can Parkinson's disease be diagnosed?</article-title>
<source>Neurology</source>
<year>1992</year>
<volume>42</volume>
<issue>1 Suppl 1</issue>
<fpage>6</fpage>
<lpage>16</lpage>
<comment>discussion, 57-60</comment>
<pub-id pub-id-type="pmid">1549203</pub-id>
</element-citation>
</ref>
<ref id="b48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calne</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Snow</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Criteria for diagnosing Parkinson's disease</article-title>
<source>Ann Neurol</source>
<year>1992</year>
<volume>32</volume>
<issue>Suppl</issue>
<fpage>S125</fpage>
<lpage>S127</lpage>
<pub-id pub-id-type="pmid">1510370</pub-id>
</element-citation>
</ref>
<ref id="b49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>WR</given-names>
</name>
</person-group>
<article-title>Research diagnostic criteria for Parkinson's disease</article-title>
<source>Adv Neurol</source>
<year>1990</year>
<volume>53</volume>
<fpage>245</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">2239463</pub-id>
</element-citation>
</ref>
<ref id="b50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajput</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Rozdilsky</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rajput</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Accuracy of clinical diagnosis in parkinsonism—a prospective study</article-title>
<source>Can J Neurol Sci</source>
<year>1991</year>
<volume>18</volume>
<fpage>275</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="pmid">1913360</pub-id>
</element-citation>
</ref>
<ref id="b51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsen</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Dupont</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tandberg</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence</article-title>
<source>Acta Neurol Scand</source>
<year>1994</year>
<volume>89</volume>
<fpage>242</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">8042440</pub-id>
</element-citation>
</ref>
<ref id="b52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aerts</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Esselink</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Post</surname>
<given-names>B</given-names>
</name>
<name>
<surname>van de Warrenburg</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Bloem</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Improving the diagnostic accuracy in parkinsonism: a three-pronged approach</article-title>
<source>Pract Neurol</source>
<year>2012</year>
<volume>12</volume>
<fpage>77</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">22450452</pub-id>
</element-citation>
</ref>
<ref id="b53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velseboer</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Wieling</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>de Bie</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis</article-title>
<source>Parkinsonism Relat Disord</source>
<year>2011</year>
<volume>17</volume>
<fpage>724</fpage>
<lpage>729</lpage>
<pub-id pub-id-type="pmid">21571570</pub-id>
</element-citation>
</ref>
<ref id="b54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Martin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rodriguez-Blazquez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kurtis</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Chaudhuri</surname>
<given-names>KR</given-names>
</name>
</person-group>
<article-title>The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease</article-title>
<source>Mov Disord</source>
<year>2011</year>
<volume>26</volume>
<fpage>399</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="pmid">21264941</pub-id>
</element-citation>
</ref>
<ref id="b55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kilford</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>1992</year>
<volume>55</volume>
<fpage>181</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="pmid">1564476</pub-id>
</element-citation>
</ref>
<ref id="b56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louis</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Mild parkinsonian signs: an overview of an emerging concept</article-title>
<source>Mov Disord</source>
<year>2007</year>
<volume>22</volume>
<fpage>1681</fpage>
<lpage>1688</lpage>
<pub-id pub-id-type="pmid">17534951</pub-id>
</element-citation>
</ref>
<ref id="b57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchman</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Shulman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Nag</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Nigral pathology and parkinsonian signs in elders without Parkinson disease</article-title>
<source>Ann Neurol</source>
<year>2012</year>
<volume>71</volume>
<fpage>258</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="pmid">22367997</pub-id>
</element-citation>
</ref>
<ref id="b58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uemura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wada-Isoe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakashita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Mild parkinsonian signs in a community-dwelling elderly population sample in Japan</article-title>
<source>J Neurol Sci</source>
<year>2011</year>
<volume>304</volume>
<fpage>61</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">21377694</pub-id>
</element-citation>
</ref>
<ref id="b59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lost</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>MX</given-names>
</name>
<name>
<surname>Schupf</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mayeux</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Functional correlates and prevalence of mild parkinsonian signs in a community population of older people</article-title>
<source>Arch Neurol</source>
<year>2005</year>
<volume>62</volume>
<fpage>297</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="pmid">15710859</pub-id>
</element-citation>
</ref>
<ref id="b60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchman</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Nag</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shulman</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease</article-title>
<source>Mov Disord</source>
<year>2012</year>
<volume>27</volume>
<fpage>1625</fpage>
<lpage>1631</lpage>
<pub-id pub-id-type="pmid">23038629</pub-id>
</element-citation>
</ref>
<ref id="b61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease</article-title>
<source>Neurology</source>
<year>2001</year>
<volume>57</volume>
<fpage>1497</fpage>
<lpage>1499</lpage>
<pub-id pub-id-type="pmid">11673599</pub-id>
</element-citation>
</ref>
<ref id="b62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tolosa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wenning</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Poewe</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>The diagnosis of Parkinson's disease</article-title>
<source>Lancet Neurol</source>
<year>2006</year>
<volume>5</volume>
<fpage>75</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">16361025</pub-id>
</element-citation>
</ref>
<ref id="b63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Ben-Shlomo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service</article-title>
<source>Brain</source>
<year>2002</year>
<volume>125</volume>
<fpage>861</fpage>
<lpage>870</lpage>
<pub-id pub-id-type="pmid">11912118</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</pmc>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>Canada</li>
<li>Espagne</li>
<li>France</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region>
<li>Californie</li>
<li>Connecticut</li>
<li>Illinois</li>
<li>Pennsylvanie</li>
<li>Tyrol (Land)</li>
<li>État de New York</li>
</region>
<settlement>
<li>Innsbruck</li>
<li>Paris</li>
</settlement>
<orgName>
<li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree>
<country name="Allemagne">
<noRegion>
<name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
</noRegion>
<name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
<name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
<name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>
</country>
<country name="Canada">
<noRegion>
<name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B" last="Postuma">Ronald B. Postuma</name>
</noRegion>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
</country>
<country name="Pays-Bas">
<noRegion>
<name sortKey="Bloem, Bastiaan" sort="Bloem, Bastiaan" uniqKey="Bloem B" first="Bastiaan" last="Bloem">Bastiaan Bloem</name>
</noRegion>
</country>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Chan, Piu" sort="Chan, Piu" uniqKey="Chan P" first="Piu" last="Chan">Piu Chan</name>
</noRegion>
</country>
<country name="France">
<noRegion>
<name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
</noRegion>
</country>
<country name="États-Unis">
<region name="Illinois">
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
</region>
<name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name>
<name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name>
<name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
</country>
<country name="Australie">
<noRegion>
<name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M" last="Halliday">Glenda M. Halliday</name>
</noRegion>
</country>
<country name="Royaume-Uni">
<noRegion>
<name sortKey="Hardy, John" sort="Hardy, John" uniqKey="Hardy J" first="John" last="Hardy">John Hardy</name>
</noRegion>
</country>
<country name="Espagne">
<noRegion>
<name sortKey="Obeso, Jose" sort="Obeso, Jose" uniqKey="Obeso J" first="José" last="Obeso">José Obeso</name>
</noRegion>
</country>
<country name="Autriche">
<region name="Tyrol (Land)">
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000004 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000004 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:4204150
   |texte=   Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i   -Sk "pubmed:24619848" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024